Epsametostat
Cancer
Haihe Biopharma Co., Ltd.Small moleculePhase 1/2Active
CC
40/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 59/ 100
Competitive context
1379 Active assets in the Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nabiximols Jazz Pharmaceuticals | Phase 3 | BBB |
Pyridoxol M.D. Anderson Cancer Center | Phase 4 | BB |
Rivoceranib Jiangsu HengRui Medicine Co., Ltd. | Phase 4 | BB |
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BB |
Propofol Hong Kong Children's Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Epsametostat is also rated in:
peripheral T-cell lymphoma, not otherwise specifiedActive
CC
Indicative · Phase 1/2
43 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →